RxDoctor Payments Data

Peter Aldana, MD

Neurology · Ft Pierce, FLNPI 1386726545

Payments from drug & device makers

$12,050in general payments, 2019–2025

Across 369 payments — averaging $32.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Livanova USA, Inc.$2K
  • AbbVie$1K
  • UCB, Inc.$921
  • Lilly USA, LLC$482
  • Eisai Inc.$470
  • plus $4K from 39 others

What the payments were for

  • Travel & lodging$1,27011%
  • Food & beverage$8,09967%
  • Education$110%
  • Gifts$2,67022%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,050 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$206,549
Medicare patients
456
Services billed
1,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate77$158,198
RexultiBrexpiprazole60$89,975
BriviactBrivaracetam46$68,774
XcopriCenobamate48$55,217
Aimovig AutoinjectorErenumab-Aooe56$49,462
UbrelvyUbrogepant46$48,469
GocovriAmantadine Hcl19$36,141
NayzilamMidazolam22$28,561
Lacosamide112$27,100
Glatiramer Acetate11$27,060
Emgality PenGalcanezumab-Gnlm30$21,265
BotoxOnabotulinumtoxina12$14,115
Memantine Hcl379$10,855
Levetiracetam364$9,831
Quetiapine Fumarate91$8,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$284$158,19877 claims
UCB, Inc.Briviact, Nayzilam$921$97,33668 claims
Otsuka America Pharmaceutical, Inc.Rexulti$32$89,97560 claims
AbbVieUbrelvy, Botox$1,328$62,58558 claims
SK Life Science, Inc.Xcopri$382$55,21748 claims
MDD US Operations, LLCGocovri$232$36,14119 claims
PfizerDilantin$85$4,45814 claims
Upsher-smith Laboratories LLCTopiramate$111$4,079207 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.

Other neurology in Ft Pierce

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →